Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nurix Therapeutics Inc NRIX

Healthcare Biotechnology
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug... see more

Recent & Breaking News (NDAQ:NRIX)

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL

GlobeNewswire January 16, 2024

Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases

GlobeNewswire January 8, 2024

Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 2, 2024

Judith A. Reinsdorf and Katherine M. Sandstrom Named to Toll Brothers Board of Directors

GlobeNewswire December 13, 2023

Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton's Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting

GlobeNewswire December 11, 2023

Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual Meeting

GlobeNewswire December 4, 2023

Nurix Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire November 7, 2023

Nurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual Meeting

GlobeNewswire November 2, 2023

Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial

GlobeNewswire November 1, 2023

Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

GlobeNewswire October 12, 2023

Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics

GlobeNewswire September 7, 2023

Nurix Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire August 31, 2023

Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

GlobeNewswire July 13, 2023

Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications

GlobeNewswire June 14, 2023

Nurix Therapeutics to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

GlobeNewswire May 9, 2023

Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance Mutations

GlobeNewswire April 17, 2023

Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

GlobeNewswire April 13, 2023

Nurix Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference

GlobeNewswire April 11, 2023

Gilead Exercises Option to License Nurix's IRAK4 Targeted Protein Degrader Development Candidate, NX-0479

GlobeNewswire March 20, 2023

Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting

GlobeNewswire March 14, 2023